Table 1.

Local and systemic IgA responses to CS6 and CS5 among patients and vaccinees as determined by immunoblotting

Patient or vaccineeCF profile of infecting strainIgA response evident in:
Fecal extractPlasma/serum
CS6aIncreasebCS6a,cIncreaseb
Acute phase (pre)Convalescent phase (post)CS6CS5Acute phase (pre)Convalescent phase (post)CS6CS5
Bangladeshi patients
 ETP-007CS5+CS6+ ++(+) [ND]+ [ND]++
 ETP-009CS5+CS6+ ++++ [ND]+ [>1:4,860]
 ETP-010CS5+CS6+ (+)+++ [>1:4,860]++
 ETP-015CS5+CS6+ NDND+ [>1:4,860]++
 ETP-018CS5+CS6+ ++
 ETP-021CS5+CS6+ ++(+) [1:60]+ [1:180]++
 ETP-006CFA/I+ ++
 ETP-011CFA/I+d +++(+) [1:60](+) [1:60]
 ETP-020CFA/I+ ++(+) [1:60](+) [1:60]+
 ETP-014CS1+CS3+ ++
Vaccineese
 Bangladeshi
  ETV-001NAf (+)++(+) [1:180](+) [1:180]
  ETV-006NA(+)+++ [1:180]+
  ETV-012NA(+) [1:180]+ [1:180]++
  ETV-018NA(+)++ [1:180]+
  ETV-024NA(+)+++ [1:60]++
 Swedish
  EC-205NA+ [1:180]++
  EC-210NA(+)++
  EC-215NA(+)+(+) [1:60]+ [1:540]++
  EC-221NA+(+) [1:60]+
  EC-240NA(+)+(+) [1:60](+) [1:60]+
  • a Acute-phase specimens were collected on day 0 (fecal specimens) or day 3 (plasma specimens), and convalescent-phase specimens were collected on day 9 after hospitalization. Prevaccination specimens (pre) were collected prior to vaccination, and postvaccination specimens (post) were collected 7 to 9 days after the second vaccination. −, no reactivity; (+), weak reactivity; +, strong reactivity against purified CS6; ND, not determined.

  • b +, increase evident.

  • c Values in brackets are the highest dilutions of the plasma or serum samples that gave positive reactions in the immunoblot assay.

  • d Coinfected with Giardia lambliacysts.

  • e Vaccinated with ETEC vaccine (lot E0001).

  • f NA, not applicable.